Citigroup Inc Sarepta Therapeutics, Inc. Put Options Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 12, 2024	BUY	$124.33 - $156.75 $484,887 - $611,325	3,900 Added 7.09%	58,900 $7.36 Million
Q2 2024 Aug 12, 2024	BUY	$113.33 - $163.85 $6.23 Million - $9.01 Million	55,000 New	55,000 $8.69 Million
Q4 2023 Feb 09, 2024	SELL	$67.31 - $124.76 $336,550 - $623,800	-5,000 Reduced 16.67%	25,000 $2.41 Million
Q3 2023 Nov 09, 2023	BUY	$102.5 - $123.59 $2.05 Million - $2.47 Million	20,000 Added 200.0%	30,000 $3.64 Million
Q2 2023 Aug 10, 2023	SELL	$106.4 - $157.19 $1.74 Million - $2.58 Million	-16,400 Reduced 62.12%	10,000 $1.15 Million
Q1 2023 May 11, 2023	BUY	$117.53 - $155.99 $2.52 Million - $3.34 Million	21,400 Added 428.0%	26,400 $3.64 Million
Q4 2022 Feb 09, 2023	SELL	$100.86 - $132.13 $2.89 Million - $3.79 Million	-28,700 Reduced 85.16%	5,000 $647,000
Q3 2022 Nov 10, 2022	BUY	$75.71 - $119.24 $2.55 Million - $4.02 Million	33,700 New	33,700 $3.73 Million

531

84.5M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.